Faculty profile

John Stagg

ResearcherOncologyUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

John Stagg

Researcher

Oncology

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
16 publications in the last five years, latest in 2026.
Senior (last) author on 5 recent papers, a sign of leading a research group.
Principal investigator on 7 research grants (7 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Immunotherapy Immune Checkpoint Adenosine Pancreatic Cancer Cancer Associated Fibroblasts Patient Selection Preclinical Models Triple Negative Breast Cancer

Latest papers

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
Nature medicine · 2026
Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.
Discover oncology · 2026
Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.
Journal for immunotherapy of cancer · 2026 · senior author

All 42 publications

Latest funding

Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer
CIHR · 2025 · Co-investigator
$918,000
Deciphering the role of protease-activated receptor 2 in immuno-oncology
CIHR · 2023 · Nominated PI
$1,013,625
Targeting the extracellular adenosine pathway in pancreatic and liver cancers
CIHR · 2021 · Nominated PI
$765,000

All 9 grants and awards

42 publications.

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.

De Caluwé A, Desmoulins I, Cao K, Remouchamps V, Baten A, Longton E, Peignaux K, Joaquin Garcia A, Venet D, Arecco L, Agostinetto E, Nader-Marta G, Denis Z, Dhont J, Kristanto P, Catteau X, Larsimont D, Salgado R, Poortmans P, Stagg J, Sotiriou C, Piccart M, Ignatiadis M, Romano E, Buisseret L

Nature medicine2026

DOI: 10.1038/s41591-026-04453-z PMID: 42350643

Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.

Catteau X, Noël JC, Fallas J, Charry M, Denis Z, De Caluwé A, Stagg J, Sotiriou C, Buisseret L

Discover oncology2026

DOI: 10.1007/s12672-026-04959-5 PMID: 42010032

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Aouad S, Kadiri M, Allard D, Skora E, Giraud L, Fuselier C, Desroys du Roure P, Mousson A, Janvier A, Baron L, Franchet C, Lecru L, Routy B, Malo J, Brugat T, Blayo AL, Schann S, Stagg J

Journal for immunotherapy of cancer2026Senior author

DOI: 10.1136/jitc-2025-013507 PMID: 41932811

ATP released by ultrasound targeted microbubble cavitation induces vascular inflammation and improves immune checkpoint blockade efficacy.

Jahangiri S, Bourdages S, Skora E, Stagg J, Yu F

Theranostics2025

DOI: 10.7150/thno.105857 PMID: 40303330

Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies.

Stagg J, Gutkind JS

Annual review of pharmacology and toxicology2025First author

DOI: 10.1146/annurev-pharmtox-061724-080852 PMID: 39270681

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC.

Desilets A, Pinheiro G, Belkaid W, Salko O, Malo J, Zarour E, Jouquan A, Thibaudeau AJ, Nolin MA, Stagg J, Florescu M, Tehfe M, Blais N, Tabchi S, Chalaoui J, Stephenson P, Elkrief A, Trinh VQ, Routy B, Liberman M

JTO clinical and research reports2024

DOI: 10.1016/j.jtocrr.2024.100737 PMID: 39624249

Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.

Allard B, Jacoberger-Foissac C, Cousineau I, Bareche Y, Buisseret L, Chrobak P, Allard D, Pommey S, Ah-Pine F, Duquenne S, Picard F, Stagg J

Cell reports. Medicine2023Senior author

DOI: 10.1016/j.xcrm.2023.101188 PMID: 37729873

The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.

Stagg J, Golden E, Wennerberg E, Demaria S

Science immunology2023First author

DOI: 10.1126/sciimmunol.abq3015 PMID: 37418547

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

Gregucci F, Spada S, Barcellos-Hoff MH, Bhardwaj N, Chan Wah Hak C, Fiorentino A, Guha C, Guzman ML, Harrington K, Herrera FG, Honeychurch J, Hong T, Iturri L, Jaffee E, Karam SD, Knott SRV, Koumenis C, Lyden D, Marciscano AE, Melcher A, Mondini M, Mondino A, Morris ZS, Pitroda S, Quezada SA, Santambrogio L, Shiao S, Stagg J, Telarovic I, Timmerman R, Vozenin MC, Weichselbaum R, Welsh J, Wilkins A, Xu C, Zappasodi R, Zou W, Bobard A, Demaria S, Galluzzi L, Deutsch E, Formenti SC

Oncoimmunology2023

DOI: 10.1080/2162402x.2023.2222560 PMID: 37363104

The CD73 immune checkpoint promotes tumor cell metabolic fitness.

Allard D, Cousineau I, Ma EH, Allard B, Bareche Y, Fleury H, Stagg J

eLife2023Senior author

DOI: 10.7554/elife.84508 PMID: 37261423

Something wrong or missing on this profile? Suggest a correction

John Stagg

Research

Latest papers

Latest funding

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.

Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

ATP released by ultrasound targeted microbubble cavitation induces vascular inflammation and improves immune checkpoint blockade efficacy.

Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies.

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC.

Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.

The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

The CD73 immune checkpoint promotes tumor cell metabolic fitness.

Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer

Deciphering the role of protease-activated receptor 2 in immuno-oncology

Targeting the extracellular adenosine pathway in pancreatic and liver cancers

MAppinG adaptatioN Of tripLe negative breast cancer microenvironments to ImmunotherApy (MAGNOLIA)

Immune-stimulatory antibody-drug conjugates for treatment of breast cancer

Targeting the CD73-adenosine pathway in cancer

Injectable thermosensitive hydrogel as delivery vehicle of lymphocytes for cancer immunotherapy

Remodeling of the tumor microenvironment by CD73: a therapeutic target

Remodeling of the tumor microenvironment by CD73: a therapeutic target

Frequent collaborators

Dominique Trudel

Dominique Trudel

Anne-Marie Mes-Masson

Bertrand Routy

Benjamin Haibe-Kains

Réjean Lapointe

Arielle Elkrief

Marie-Claude Bourgeois-Daigneault

John Stagg

Research

Latest papers

Latest funding

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.

Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

ATP released by ultrasound targeted microbubble cavitation induces vascular inflammation and improves immune checkpoint blockade efficacy.

Targeting G&#xa0;Protein-Coupled Receptors in Immuno-Oncological Therapies.

CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC.

Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma.

The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.

Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.

The CD73 immune checkpoint promotes tumor cell metabolic fitness.

Frequent collaborators

Dominique Trudel

Dominique Trudel

Anne-Marie Mes-Masson

Bertrand Routy

Benjamin Haibe-Kains

Réjean Lapointe

Arielle Elkrief

Marie-Claude Bourgeois-Daigneault

Targeting G Protein-Coupled Receptors in Immuno-Oncological Therapies.